Jun Luo

Dec 6, 2024 | mdpi.com | Guanzhong Ma |Jun Luo |Xiao Zhou

1. IntroductionLet M d ( R ) be the set of all d × d matrices with entries in R, and let A ∈ M d ( R ) be an expanding matrix. Let N ≥ 2 and n 1 , … , n N be positive integers. Write A j = A n j , 1 ≤ j ≤ N and D = { d 1 , … , d N } ⊂ R d . Then, we can define a self-affine iterated function system (IFS) { S j } j = 1 N on R d by S j ( x ) = A j − 1 ( x + d j ) , j = 1 , … , N .

Nov 13, 2024 | nature.com | Wangxin Guo |Lin Li |Jun Luo |Chen Hong Yu |Luonan Chen |Bin Zhou

AbstractUnipotent basal and luminal stem cells maintain prostate homeostasis, with an intermediate cell population emerging during prostate inflammation or cancer. However, the identities of basal stem cell and intermediate cell population remain unclear. Here we identified a rare intermediate cell population expressing luminal markers (termed Basal-B) with enhanced organoid formation capacity, and a larger basal population (termed Basal-A).

Nov 10, 2024 | nature.com | Zhiwei Chen |Jun Luo

AbstractUsing body heat for instance, thermoelectric generators have promising applications for driving wearable electronics continuously but remain a challenge in terms of recoverable flexibility, as known highly-performing thermoelectrics are usually inorganics showing rigidity. It is conceptualized in this work a large elastic strain ensuring both a largely-curved recoverable bending and a full recoverability in thermoelectric performance after enormous bendings.

Nov 5, 2024 | pericles.pericles-prod.literatumonline.com | Jie Zeng |Jun Luo |Xu Li |Yongjie Ye

Supporting Information As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

Nov 4, 2024 | nature.com | Jun Luo

In 1997, Sigurdsson et al. first reported an association between a BRCA2 founder mutation and the risk of advanced prostate cancer within the Icelandic population [1]. Landmark studies published in 2015 and 2016 further elucidated and solidified the role of BRCA2 and other DNA homologous recombination (HR) repair genes in prostate cancer [2, 3].